Bone mineral density assessment in premenopausal women

Women's Health

Volumn 2, Issue 4, 2006, Pages 639-645

  Khan, Aliya ^a   Syed, Zeba ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

Antiresorptive therapies; Depot medroxyprogesterone acetate; Fracture risk; Glucocorticoid therapy; Low bone mineral density; Oral contraceptives; Osteoporosis; Premenopausal; Prevention; Therapy

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ESTROGEN; FOLLITROPIN; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; LITHIUM; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RISEDRONIC ACID; THYROXINE; VITAMIN D;

ALCOHOL WITHDRAWAL; BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; BONE MASS; CELIAC DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EXERCISE; FEMALE; FRAGILITY FRACTURE; GLUTEN FREE DIET; GRANULOMATOSIS; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; LIFESTYLE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; WEIGHT REDUCTION;

EID: 33745598792     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.4.639     Document Type: Review

References (38)

1. Khan A, Bachrach L, Brown J et al.: Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J. Clin. Densitom. 7, 51-63 (2004).
2. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137-1141 (1994).
3. Gullberg B, Johnell O, Kanis JA: World-wide projections for hip fracture. Osteoporos. Int. 7, 407-413 (1997).
4. Hui SL, Slemenda CW, Johnston CC: Age and bone mass as predictors of fracture in a prospective study. J. Clin. Invest. 81, 1804-1809 (1988).
5. Sowers M, Kshirsagar A, Crutchfield M, Updike S: Body composition, age and femoral bone mass of young adult women. Ann. Epidemiol. 1, 245-254 (1991).
6. Hosmer WD, Genant HK, Arowner WS: Fractures before menopause: a red flag for physicians. Osteoporos. Int. 13, 337-341 (2002).
7. Khan AA, Syed Z: Bone densitometry in premenopausal women. J. Clin. Densitom. 7(1), 85-92 (2004).
8. Prior JC, Vigna YM, Schechter MT, Burgess AE: Spinal bone loss and ovulatory disturbances. N. Engl. J. Med. 323, 1221-1227 (1990).
9. Sowers M, Randolph JF Jr, Crutchfield M et al.: Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J. Bone Miner. Res. 13, 1191-1202 (1998).
10. Sowers M, Crutchfield M, Bandekar R et al.: Bone mineral density and its change in pre- and perimenopausal white women: The Michigan Bone Health Study. J. Bone Miner. Res. 13, 1134-1140 (1998).
11. Sowers M, Clark MK, Hollis B et al.: Radial bone mineral density in pre- and perimenopausal women: A prospective study of rates and risk factors of loss. J. Bone Miner. Res. 7, 647-657 (1992).
12. Warming L, Hassager C, Christiansen C: Changes in bone mineral density with age in men and women: A longitudinal study. 0steoporos. Int. 13, 105-112 (2002).
13. LoCascio V, Bonucci E, Imbimbo B et al.: Bone loss after glucocorticoid therapy. Calcif. Tissue Int. 36(4), 435-438 (1984).
14. Adachi JD, Bensen WG, Bianchi F et al.: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followup. J. Rheumatol. 23(6), 995-1000 (1996).
15. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15(6), 993-1000 (2000).
16. Kanis JA, Johansson H, Oden A et al.: A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19(6), 893-899 (2004).
17. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48(11), 3224-3229 (2003).
18. Khan AA, Hanley DA, Bilezikian JP et al.: Standards for performing DXA in individuals with secondary causes of osteoporosis. J. Clin. Densitom. 9(1), 47-57 (2006).
19. Adachi JD, Bensen WG, Brown J et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337(6), 382-387 (1997).
20. Saag KG, Emkey R, Schnitzer TJ et al.: Alendronate for the prevention and treatment of glucocorticoid-Induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339(5), 292-299 (1998).
21. Wallach S, Cohen S, Reid DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67(4), 277-285 (2000).
22. Donnan PT, Libby G, Boyter AC, Thompson P: The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol. Drug Saf. 14(3), 177-186 (2005).
23. Fraser IS, Weisberg E: A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med. J. Aust. 24(Suppl. 1), 3-19 (1981).
24. Jeppsson S, Johansson ED: Medroxyprogesterone acetate, estradiol, FSH, and LH in peripheral blood after intramuscular administration of Depo-Provera® to women. Contraception 14, 461-469 (1976).
25. Paiva LC, Pinto-Neto AM, Faundes A: Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 58, 351-355 (1988).
26. Wanichsetakul P, Kamudhamas A, Watanaruagniobit P et al.: Bone mineral density at various anatomic bone sites in women receiving oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 65, 407-510 (2002).
27. Scholes D, Lacroix AZ, Ott SM et al: Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Arch. Pediatr. Adolesc. Med. 159(2), 139-144 (2005).
28. Saag KG, Emkey R, Schnitzer TJ et al., for the Glucorticoid-Induced Osteoporosis Intervention Study Group: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339, 292-299 (1998).
29. Adachi JD, Saag KG, Delmas PD et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202-211 (2001).
30. Reid DM, Hughes RA, Laan RF et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid induced osteoporosis in men and women: A randomized trial. European Corticosteroid- Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006-1013 (2000).
31. Wallach S, Cohen S, Reid DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277-285 (2000).
32. Khan AA, Bilezikian JP, Kung AW et al.: Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89(7), 3319-3325 (2004).
33. Brown JP, Josse RG: Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can. Med. Assoc. J. 167(10), S1-S35 (2002).
34. Kuohung W, Borgatta L, Stubblefield P: Low dose oral contraceptives and bone mineral density: An evidence based analysis Contraception 61(2), 77-82 (2000).
35. Prior JC, Vigna YM, Barr SI, Rexworth C, Lentle BC: Cylic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances: Am. J. Med. 96, 521-520 (1994).
36. DeCherney A: Bone-sparing properties of oral contraceptives. Am. J. Obstet. Gynecol. 174, 15-20 (1996).
37. Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE: Effects of contraceptive use on bone biochemical markers in young women. J. Clin. Endocrinol. Metab. 86, 179-185 (2001).
38. Prior JC, Kirkland SA, Joseph L et al.: Oral contraceptive use and bone mineral density in premenopausal women: Cross-sectional, population based data from the Canadian Multicentre Osteoporosis Study. Can. Med. Assoc. J. 165(8), 1023-1029 (2001).